| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
52,373,000 |
| Market
Cap: |
2.52(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$30.85 - $52.9 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Laboratories & Research |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 474 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Vericel is a biopharmaceutical company providing cell therapies for the sports medicine and severe burn care markets. Co.'s products include: MACI®, which is an autologous cellularized scaffold product indicated for the repair of symptomatic, full-thickness cartilage defects of the knee with or without bone involvement in adults; and Epicel®, which is a permanent skin replacement for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area. Co. also holds a license for North American rights to NexoBrid®, a registration-stage biological orphan product for debridement of severe thermal burns.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
134,738 |
259,234 |
263,234 |
303,833 |
| Total Sell Value |
$6,189,261 |
$10,761,080 |
$10,907,920 |
$12,010,179 |
| Total People Sold |
5 |
7 |
7 |
7 |
| Total Sell Transactions |
12 |
29 |
31 |
34 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Zerbe Robert L Md |
|
• • – |
2024-01-22 |
4 |
OE |
$4.12 |
$12,360 |
D/D |
3,000 |
28,895 |
|
- |
|
| Colangelo Dominick |
President and CEO |
• • – |
2024-01-18 |
4 |
AS |
$38.58 |
$645,289 |
D/D |
(16,726) |
169,985 |
|
23% |
|
| Colangelo Dominick |
President and CEO |
• • – |
2024-01-18 |
4 |
OE |
$3.02 |
$50,513 |
D/D |
16,726 |
186,711 |
|
- |
|
| Colangelo Dominick |
President and CEO |
• • – |
2024-01-17 |
4 |
AS |
$37.97 |
$635,086 |
D/D |
(16,726) |
169,985 |
|
27% |
|
| Colangelo Dominick |
President and CEO |
• • – |
2024-01-17 |
4 |
OE |
$3.02 |
$50,513 |
D/D |
16,726 |
186,711 |
|
- |
|
| Zerbe Robert L Md |
|
• • – |
2024-01-12 |
4 |
AS |
$38.09 |
$83,798 |
D/D |
(2,200) |
30,895 |
|
26% |
|
| Flynn Sean C. |
SVP, General Counsel |
• • – |
2023-12-14 |
4 |
S |
$37.45 |
$3,970 |
D/D |
(106) |
4,467 |
|
-24% |
|
| Colangelo Dominick |
President and CEO |
• • – |
2023-12-14 |
4 |
AS |
$37.12 |
$445,440 |
D/D |
(12,000) |
169,985 |
|
24% |
|
| Colangelo Dominick |
President and CEO |
• • – |
2023-12-14 |
4 |
OE |
$3.57 |
$42,840 |
D/D |
12,000 |
181,985 |
|
- |
|
| Wotton Paul K |
|
• • – |
2023-12-14 |
4 |
S |
$37.31 |
$186,550 |
D/D |
(5,000) |
26,802 |
|
-24% |
|
| Flynn Sean C. |
SVP, General Counsel |
• • – |
2023-12-13 |
4 |
S |
$34.20 |
$48,974 |
D/D |
(1,432) |
4,573 |
|
-28% |
|
| Colangelo Dominick |
President and CEO |
• • – |
2023-12-13 |
4 |
AS |
$34.03 |
$408,360 |
D/D |
(12,000) |
169,985 |
|
28% |
|
| Colangelo Dominick |
President and CEO |
• • – |
2023-12-13 |
4 |
OE |
$3.57 |
$42,840 |
D/D |
12,000 |
181,985 |
|
- |
|
| Colangelo Dominick |
President and CEO |
• • – |
2023-12-13 |
4 |
GD |
$0.00 |
$0 |
D/D |
6,757 |
169,985 |
|
- |
|
| Colangelo Dominick |
President and CEO |
• • – |
2023-12-07 |
4 |
AS |
$33.84 |
$406,080 |
D/D |
(12,000) |
176,742 |
|
28% |
|
| Colangelo Dominick |
President and CEO |
• • – |
2023-12-07 |
4 |
OE |
$3.57 |
$42,840 |
D/D |
12,000 |
188,742 |
|
- |
|
| Colangelo Dominick |
President and CEO |
• • – |
2023-12-06 |
4 |
AS |
$34.43 |
$426,829 |
D/D |
(12,397) |
176,742 |
|
30% |
|
| Colangelo Dominick |
President and CEO |
• • – |
2023-12-06 |
4 |
OE |
$3.57 |
$44,257 |
D/D |
12,397 |
189,139 |
|
- |
|
| Halpin Michael |
Chief Operating Officer |
• • – |
2023-11-30 |
4 |
AS |
$35.41 |
$617,798 |
D/D |
(17,447) |
827 |
|
37% |
|
| Halpin Michael |
Chief Operating Officer |
• • – |
2023-11-30 |
4 |
OE |
$7.20 |
$125,618 |
D/D |
17,447 |
18,274 |
|
- |
|
| Hopper Jonathan Mark |
Chief Medical Officer |
• • – |
2023-11-20 |
4 |
AS |
$36.40 |
$182,000 |
D/D |
(5,000) |
53,007 |
|
40% |
|
| Hopper Jonathan Mark |
Chief Medical Officer |
• • – |
2023-11-20 |
4 |
OE |
$10.95 |
$54,750 |
D/D |
5,000 |
58,007 |
|
- |
|
| Zerbe Robert L Md |
|
• • – |
2023-11-15 |
4 |
AS |
$38.00 |
$11,406 |
D/D |
(300) |
33,095 |
|
45% |
|
| Flynn Sean C. |
SVP, General Counsel |
• • – |
2023-11-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,042 |
6,005 |
|
- |
|
| Siegal Jonathan |
Principal Accounting Officer |
• • – |
2023-11-15 |
4 |
S |
$37.70 |
$24,954 |
D/D |
(662) |
1,305 |
|
-45% |
|
394 Records found
|
|
Page 3 of 16 |
|
|
0.55 (1.13%) 
